RU2013126798A - Комбинированная терапия дексаметазоном - Google Patents
Комбинированная терапия дексаметазоном Download PDFInfo
- Publication number
- RU2013126798A RU2013126798A RU2013126798/15A RU2013126798A RU2013126798A RU 2013126798 A RU2013126798 A RU 2013126798A RU 2013126798/15 A RU2013126798/15 A RU 2013126798/15A RU 2013126798 A RU2013126798 A RU 2013126798A RU 2013126798 A RU2013126798 A RU 2013126798A
- Authority
- RU
- Russia
- Prior art keywords
- amount
- subject
- ylamine
- morpholin
- pyrimidin
- Prior art date
Links
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 title claims abstract 9
- 238000002648 combination therapy Methods 0.000 title claims 2
- 238000000034 method Methods 0.000 claims abstract 16
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims abstract 9
- 229960003957 dexamethasone Drugs 0.000 claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 8
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract 7
- 239000002552 dosage form Substances 0.000 claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 239000002207 metabolite Substances 0.000 claims abstract 3
- 238000011260 co-administration Methods 0.000 claims abstract 2
- 238000009472 formulation Methods 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41326010P | 2010-11-12 | 2010-11-12 | |
| US61/413,260 | 2010-11-12 | ||
| US42008910P | 2010-12-06 | 2010-12-06 | |
| US61/420,089 | 2010-12-06 | ||
| PCT/US2011/060297 WO2012065021A1 (en) | 2010-11-12 | 2011-11-11 | Dexamethasone combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013126798A true RU2013126798A (ru) | 2014-12-20 |
Family
ID=45094245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013126798/15A RU2013126798A (ru) | 2010-11-12 | 2011-11-11 | Комбинированная терапия дексаметазоном |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130310352A1 (enExample) |
| EP (1) | EP2637665B1 (enExample) |
| JP (1) | JP2013542262A (enExample) |
| KR (1) | KR20140009222A (enExample) |
| CN (1) | CN103313714A (enExample) |
| AU (1) | AU2011326394A1 (enExample) |
| BR (1) | BR112013011728A2 (enExample) |
| CA (1) | CA2816601A1 (enExample) |
| MX (1) | MX2013005271A (enExample) |
| RU (1) | RU2013126798A (enExample) |
| WO (1) | WO2012065021A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| WO2020168106A1 (en) | 2019-02-13 | 2020-08-20 | Notable Labs, Inc. | Combinations of agonists of protein kinase c with steroids or retinoic acids for the treatment of cancer |
| KR20220110243A (ko) * | 2019-12-02 | 2022-08-05 | 셀진 코포레이션 | 암의 치료를 위한 요법 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
-
2011
- 2011-11-11 US US13/884,862 patent/US20130310352A1/en not_active Abandoned
- 2011-11-11 RU RU2013126798/15A patent/RU2013126798A/ru not_active Application Discontinuation
- 2011-11-11 MX MX2013005271A patent/MX2013005271A/es not_active Application Discontinuation
- 2011-11-11 JP JP2013538921A patent/JP2013542262A/ja not_active Withdrawn
- 2011-11-11 CN CN2011800544683A patent/CN103313714A/zh active Pending
- 2011-11-11 KR KR1020137013791A patent/KR20140009222A/ko not_active Withdrawn
- 2011-11-11 AU AU2011326394A patent/AU2011326394A1/en not_active Abandoned
- 2011-11-11 BR BR112013011728A patent/BR112013011728A2/pt not_active IP Right Cessation
- 2011-11-11 EP EP11791122.2A patent/EP2637665B1/en not_active Revoked
- 2011-11-11 WO PCT/US2011/060297 patent/WO2012065021A1/en not_active Ceased
- 2011-11-11 CA CA2816601A patent/CA2816601A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2637665A1 (en) | 2013-09-18 |
| KR20140009222A (ko) | 2014-01-22 |
| BR112013011728A2 (pt) | 2016-08-16 |
| US20130310352A1 (en) | 2013-11-21 |
| JP2013542262A (ja) | 2013-11-21 |
| CN103313714A (zh) | 2013-09-18 |
| WO2012065021A1 (en) | 2012-05-18 |
| MX2013005271A (es) | 2013-09-26 |
| AU2011326394A1 (en) | 2013-05-30 |
| CA2816601A1 (en) | 2012-05-18 |
| EP2637665B1 (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| JP2012193216A5 (enExample) | ||
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| MX2020003381A (es) | Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma. | |
| JP2016518387A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| JP2015038135A5 (enExample) | ||
| EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| FI3493812T3 (fi) | Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten | |
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| BRPI0710682B8 (pt) | combinação farmacêutica compreendendo 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol e paracetamol | |
| JP2016505050A5 (enExample) | ||
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| JP2015512948A5 (enExample) | ||
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| JP2012041314A5 (enExample) | ||
| RU2020108631A (ru) | Новая вспомогательная терапия для применения в способе лечения рака простаты | |
| MX384760B (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático. | |
| RU2013149635A (ru) | Соединения солифенацина и слюнные стимулянты для лечения гиперактивности мочевого пузыря | |
| JP2013542262A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160212 |